KRAS and lung adenocarcinoma: reported that IGF2BP1 can synergize with KRAS to promote the malignant phenotypes of mouse lung adenocarcinoma in vitro and in vivo, although the isolated overexpression of IGF2BP1 had no noticeable effect (31).